Evidence map›Paper›PMID 34425358›Full record

ArticleJournal of infection and public health2021

Evaluation of a combination protocol of CT-first triage and active telemedicine methods by a selected team tackling COVID-19: An experimental research study.

Shigeta Miyake, Takuma Higurashi, Hideaki Kato, Yutaro Yamaoka, Takaomi Kessoku, Shingo Kato, Fumihiro Ogawa, Yasufumi Oi, Atsushi Nakajima, Tetsuya Yamamoto and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of infection and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Shigeta MiyakeTeam COVID-19, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan; Department of Neurosurgery, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan.
Takuma HigurashiTeam COVID-19, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan; Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan. Electronic address: takuma_h@yokohama-cu.ac.jp.
Hideaki KatoTeam COVID-19, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan; Infection Prevention and Control Department, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa-ku, Japan.
Yutaro YamaokaDepartment of Microbiology, Yokohama City University School of Medicine, Kanagawa 236-0004, Japan; Life Science Laboratory, Technology and Development Division, Kanto Chemical Co., Inc., Kanagawa 259-1146, Japan.
Takaomi KessokuDepartment of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan; Palliative Care Medicine Department, Yokohama City University Hospital, 3-9, Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Shingo KatoDepartment of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan; Department of Clinical Cancer Genomics, Yokohama City University, 3-9, Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Fumihiro OgawaTeam COVID-19, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan; Department of Emergency Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan.
Yasufumi OiTeam COVID-19, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan; Department of Emergency Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan.
Atsushi NakajimaTeam COVID-19, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan; Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan.
Tetsuya YamamotoTeam COVID-19, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan; Department of Neurosurgery, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan.
Ichiro TakeuchiTeam COVID-19, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan; Department of Emergency Medicine, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan.
Akihide RyoDepartment of Microbiology, Yokohama City University School of Medicine, Kanagawa 236-0004, Japan.
Shin MaedaTeam COVID-19, Yokohama City University Hospital, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan; Department of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, Yokohama 2360004, Japan.
Yokohama City University Hospital · JPYokohama City University · JPKanagawa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany health care workers around the world tackled with COVID-19, however sadly, the infection of many medical care workers were reported. To reduce the risk of infection, we launched selected team (Team COVID) of non-specialists and brought in active telemedicine method and computed tomography (CT)-first protocol. We describe our actual practice and the health status of medical doctors dealing with COVID-19 patients.

methodsBetween April 17, 2020 and May 24, 2020, 10 doctors worked with COVID-19 patients as part of Team COVID. The Team COVID doctors used a CT-first triage protocol for outpatients and telemedicine for inpatients and outpatients. We evaluated paired serum-specific antibodies for SARS-CoV-2 at the initial and end of the study duration and PCR results for SARS-CoV-2 at the end of the study duration. Furthermore, 36-item short-form of the Medical Outcome Study Questionnaire (SF-36) at the beginning and end of the study period were evaluated.

resultsTen doctors worked as Team COVID: seven internal medicine doctors and three surgeons. During the study period, Team COVID treated 165 individuals in the outpatient clinic and isolated hospitalized patients for 315 person-days. There were no positive results of serum-specific antibody testing and PCR testing for SARS-CoV-2 in Team COVID doctors. Furthermore, the SF-36 showed no deterioration in physical and mental QOL status. No in-hospital infection occurred during the study period.

conclusionsThe Team COVID fulfilled the treatment using the active telemedicine and CT-first triage protocol without in hospital infection and excess stress. The combination strategy seems acceptable for both the protection and stress relief among the medical staff.

Indexed as

COVID-19TelemedicineHumansQuality of LifeSARS-CoV-2Tomography, X-Ray ComputedTriageCOVID-19CT-first triageHealth of medical stuffMedical care teamTelemedicine

Identifiers

PMID34425358
PMCPMC8372458
OpenAlexW3195719168

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.